Anticancer agent 358

Anticancer agent 358 (compound 14 h) (10-80 μM; 72 h) potently inhibits the proliferation of A549, PC-9, H460, and H1299 human lung cancer cells with IC₅₀ values of 13.87 μM, 3.81 μM, 10.01 μM, and minimal cytotoxicity against normal L02 liver cells^[1].
Anticancer agent 358 (5-20 μM; 24 h) induces dose-dependent cell death in A549, PC-9, and H460 human lung cancer cells, with a particularly pronounced effect in PC-9 cells^[1].
Anticancer agent 358 (5-20 μM; 24 h) induces significant DNA damage in A549, PC-9, and H460 human lung cancer cells^[1].
Anticancer agent 358 effectively binds to the active site of the PARP protein through key hydrogen bonding and π-π stacking interactions, suggesting potential PARP inhibition activity^[1].
Anticancer agent 358 (5-20 μM; 72 h) promotes apoptosis in A549 and H460 human lung cancer cells but does not significantly induce apoptosis in PC-9 human lung cancer cells^[1].
Anticancer agent 358 (5-20 μM; 72 h) upregulates the expression of key proteins involved in DNA damage and apoptosis, including caspase-9, γH2AX, and PARP, in A549, PC-9, and H460 human lung cancer cells^[1].
Anticancer agent 358 (5-20 μM; 24 h) induces dose-dependent autophagy in A549, PC-9, and H460 human lung cancer cells^[1].
Anticancer agent 358 (5-20 μM; 72 h) modulates the expression of key genes involved in DNA damage response, oxidative stress, apoptosis, and autophagy in a cell line-specific manner, with significant upregulation of p21, Bcl-2, caspase-6, Keap1, and ATG7 in H460 human lung cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.